Hyperlipoproteinemia in children

Czech version

Authors: Zuzana Urbanová
Authors‘ workplace: Klinika dětského a dorostového lékařství 1. LF UK a VFN v Praze
Published in: Vnitř Lék 2016; 62(11): 882-886
Category: Reviews

Overview

Hyperlipoproteinemia (HLP) is one of the most common metabolic disorder in childhood. We assume that 20 % of children have a disorder of the lipid metabolism. Some HLP are very common in the population, and moderate, and some are very rare, but are very severe. These may occur secondary to pathological conditions, or are formed on the basis of the primary monogenic or polygenic disorders of lipid metabolism. The detection of children with HLP in the Czech Republic is either random, or more often by selective screening of children with familial history of cardiovascular disease, provided by general pediatric practitioners for children and adolescents. Treatment in childhood is primarily dietetic, some of them, especially children with familial hypercholesterolemia are treated from 8–10 years pharmacologically.

Key words:
diagnosis – hyperlipoproteinemia – children – treatment

Sources

1. Berenson GS, Srinivasan S, Bao W et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults: the Bogalusa Heart Study. N Engl J Med 1998; 338(23): 1650–1656.

2. Šamánek M, Urbanová Z. Prevence aterosklerózy v dětském věku. Galén: Praha 2003. ISBN 80–7262–229–3.

3. Češka R. Diagnostika a léčba hyperlipoproteinémií. Triton: Praha 2003. ISBN 80–7254–328–8.

4. National Cholesterol Education Program (NCEP): highlights of the report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics 1992; 89(3):495–501.

5. Urbanová Z, Šamánek M, Češka R et al. Doporučení pro diagnostiku a léčbu dyslipidemií u dětí a dospívajících, vypracované výborem České společnosti pro aterosklerózu. Cor et Vasa 2008; 50(2): K41-K47.

6. Kavey RW, Stephen R, Lauer MR et al. American Heart Association Guidelines for Primary Prevention of Atherosclerotic Cardiovascular Disease Beginning in Childhood. Circulation 2003; 107(11): 1562–1566.

7. Stephen R, Daniels MD, Gidding SS et al. Pediatric aspects of Familial Hypercholesterolemia: Recommendation from the National Lipid Association Expert Panel on Familial hypercholesterolemia. J Clin Lipidol 2011; 5(3 Suppl): S30-S37. Dostupné z DOI: <http://dx.doi.org/http://dx.doi.org/10.1016/j.jacl.2011.03.453>.

8. Wiegman A, Gidding S, Wats GF et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J 2015; 36(36): 2425–37. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehv157>.

9. Bibbins-Domingo K, Grossman DC, Curry SJ et al. [US Preventive Services Task Force]. Screening for Lipid Disorders in Children and Adolescents: US Preventive Services Task Force Recommendation Statement. JAMA 2016; 316(6): 625–633. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2016.9852>.

10. Urbanová Z, Freiberger T, Šamánek M et al. Komentář k souhrnu konsenzu panelu experů European Atherosclerotic Society k otázce optimalizace diagnostiky a léčby dětí s familiární hypercholesterolemií. Hypertenze a kardiovaskulární prevence 2016; 5(1): 36–38. Dostupné z WWW: <http://www.hypertension.cz/sqlcache/csh-01–2016-web.pdf>.